Skip to main content

news

 

Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.

Kirkland & Ellis offered legal advice to the financial advisor, China International Capital Corporation (CICC), in the deal.

Henlius, established in 2010, was listed in Hong Kong in September 2019. Its product portfolio covers areas such as oncology, autoimmune diseases, and ophthalmic diseases. The company has launched five products in China and has three products approved for international markets. In 2023, the company achieved its first annual profit.

The Freshfields team was led by partners Edward Freeman, Grace Huang, and David Yi.

The Kirkland team was led by corporate partners Joey Chau and Nelson Ni, with assistance from debt finance partners Jacqueline Zheng and Sean Zhang.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.